Two leading drugs have announced new clinical data for patients with Duchenne muscular dystrophy (DMD) which show a maintenance of treatment effect, equivalent to two years in decline for time to stand (TTstand). Scientists say they believe the drug s safety and tolerability benefits are significant.
Source: pharmiweb.comPublished on 2021-04-29
Related news
- Questions and Answers on Revised EU rules on Industrial Emissions
- Algorithm and blues : avoiding the traps in new tech
- Revised EU rules on industrial emissions EUbusiness . com | EU news , business and politics
- State Comptroller DiNapoli Releases Audits
- Digital Government - GOV . UK
- Where the dollars go : Lobbying a big business for large food and beverage CPGs
- Enel X launches the first Circular City Index for Italian municipalities
- Virtual Panel : How Open - Source is Helping to Change the World
- Unlocking The Power Of Data : Making Better Business Decisions
- How police can use smart technology to improve community relations
- Schlumberger Launches Enterprise Data Solution
- Evergreen partners with local Ontario conservation authority and Peel Region for next phase of AI for the Resilient City
- Staff on salaries over 100k at Watford and Hertfordshire councils
- Santhera and ReveraGen Announce New 2 . 5 - year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy
- What will it take for open banking to take hold in the U . S .?